Secondary Logo

GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks

MacManus, Sarah; Yates, Phillip J; Elston, Robert C; White, Susan; Richards, Naomi; Snowden, Wendy

CLINICAL SCIENCE: CONCISE COMMUNICATION
Free
SDC

Objectives: To investigate the emergence of resistance to GW433908 (908), a protease inhibitor (PI) with demonstrated antiviral efficacy, safety and tolerability, when administered once daily (q.d.) with low dose ritonavir (908/r).

Design: A 48-week Phase III open-label study (SOLO, APV30002) in which antiretroviral therapy-naive patients (n = 649) were treated with 908/r, (1400 mg/200 mg, q.d.) or nelfinavir [1250 mg, twice daily (b.i.d.)] with two nucleoside reverse transcriptase inhibitors (NRTI), abacavir (300 mg, b.i.d.) and lamivudine (150 mg, b.i.d.).

Methods: Viral genotype and phenotype were analysed at baseline and on treatment up to 48 weeks and beyond.

Results: Emergence of genotypic resistance was significantly different between the 908/r q.d. and the nelfinavir b.i.d. treatment arms for both PIs (0 versus 50%; P < 0.001) and the NRTI (13% versus 69%; P < 0.001) received. In the nelfinavir arm the key protease mutations D30N and/or L90M were frequently observed. The absence of protease resistance mutations and reduced incidence of NRTI resistance mutations in the 908/r q.d. arm was confirmed by phenotyping, which showed a lack of PI cross-resistance.

Conclusions: The absence of resistance to 908 or cross-resistance to other PIs, and reduced NRTI resistance, following a 908/r q.d. regimen supports the use of this boosted PI early in therapy.

From Clinical Virology, Stevenage and Biomedical Data Sciences, Greenford, GlaxoSmithKline, UK.

Correspondence to R. C. Elston, Department of Clinical Virology, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK.

Received: 31 July 2003; revised: 2 October 2003; accepted: 8 October 2003.

Back to Top | Article Outline

Introduction

GW433908 is a potent and durable HIV protease inhibitor (PI) with a favourable safety profile as demonstrated by two Phase III clinical trials in antiretroviral-naive patients [1,2]. Co-administration of 908 with low dose ritonavir boosts exposure of amprenavir (APV) which facilitates flexible dosing, including once daily (q.d.) dosing, and requires no food or fluid restrictions [3,4].

Resistance studies with APV, the active moiety of 908, have identified four distinct genetic pathways leading to reduced susceptibility to APV [5–7]. The pathways are characterized by the protease substitutions I50V, I54L/M, V32I+I47V, or, less commonly, I84V. Other secondary mutations include L10F, L33F or M46I/L in protease and L449F or P453L in the P1/P6 Gag cleavage site [8]. Little or no cross-resistance to other PIs was detected in virus from APV failures [7].

Efficacy data from the Phase III SOLO study comparing 908/r q.d. and nelfinavir (NFV) twice daily (b.i.d.) when taken with abacavir (ABC)/lamivudine (3TC) b.i.d. has been reported [2]. Briefly, 69% and 55% in the 908/r q.d. arm and 68% and 53% in the NFV b.i.d. arm had plasma HIV-1 RNA < 400 copies/ml, and < 50 copies/ml respectively at week 48 (intent-to-treat rebound/discontinuation = failure). More of the NFV b.i.d. arm (57/327, 17%) experienced virological failure than in the 908/r q.d. arm (22/322, 7%). Resistance analysis of the virological failures in SOLO comparing 908/r q.d. with NFV b.i.d. is presented.

Back to Top | Article Outline

Methods

Study design

SOLO was a randomized, parallel, open-label, multicentre, study of 908/r 1400 mg/200 mg q.d. (n = 322) versus NFV 1250 mg b.i.d. (n = 327), in combination with ABC b.i.d. and 3TC b.i.d. Patients could remain in the study until the last patient enrolled completed the week 48 study visit. Baseline resistance was analysed by genotyping at day 1 in a random subset (169) of patients. Virologic failure was defined as an HIV-1 RNA level (vRNA) of ≥ 1000 copies/ml at two consecutive visits from week 12 or beyond, after having previously achieved vRNA of < 400 copies/ml; or having on-going viral replication defined as failing to achieve vRNA of < 400 copies/ml at week 12. The first of two consecutive samples with vRNA of ≥ 1000 copies/ml at week 12 or beyond was analysed together with the corresponding baseline sample. Evolution of resistance during therapy was analysed using the last timepoint on randomized therapy where the vRNA was > 1000 copies/ml.

Samples were assessed for viral genotype, including coding regions, protease (PRO), reverse transcriptase (RT) and p7/p1 and p1/p6 Gag cleavage sites, and for drug-susceptibility phenotype, by ViroLogic Inc. (South San Francisco, California, USA) using the GENESEQ and the PHENOSENSE assays. Genotypic comparisons were based on the wild-type HIV-1 strain, HXB2. Phenotypes were reported as fold reduction in 50% inhibitory concentration relative to wild-type strain NL4-3. Resistance observed was evaluated in relation to vRNA profiles of virological failures which were categorized based on the slope of vRNA rebound. Rebound slopes were defined as rapid, if the rebound reading was > 10 000 RNA copies/ml, unless the rebound was < 20% of baseline viral load; or gradual if the rebound reading did not exceed 10 000 RNA copies/ml, unless it was > 80% of baseline viral load. A third category included those with ongoing replication.

Back to Top | Article Outline

Results

Resistance mutations in baseline virus

Virus from only two patients (2/196; ∼1%), both in the 908/r q.d. arm, had evidence at baseline of any PRO mutations [9]. In one patient, an I50i/v mixture was detected at baseline but not following subsequent failure at week 20 of 908/r q.d. therapy. An indinavir resistance mutation L24I [9,10], and an RT revertant mutation T215D [11,12] were evident at day 1 in another patient (patient 1, Table 2). Between week 1 and week 4, additional PRO mutations M46L, I54V and V82A and an RT mutation M41L were detected. This patient responded but failed by week 12 with only M184V added after failure. The incidence of baseline nucleoside reverse transcriptase inhibitor (NRTI) resistance mutations was 6% (12/191, data unavailable for five patients) with four in the 908/r q.d. arm, (T215D; T215S; M41L+V118i/v; T215L+L100i/l+K103k/n) and eight in the NFV b.i.d. arm (T215D; L210W; E44D; V118i/v (n = 2); K219k/e; M41L+T215S; L210W+T215D).

Table 2

Table 2

Back to Top | Article Outline

Emergence of resistance mutations during therapy

Statistically significant differences (Fisher's Exact Test) were observed between the 908/r q.d. and NFV b.i.d. arms in both the incidence of selection of PRO (0 versus 50%; P < 0.001) and RT (13% versus 69%; P < 0.001) mutations (Table 1). Natural polymorphisms in the absence of any other PRO mutations were excluded from this analysis (NFV, n = 3; 908/r, n = 1). Correlation of resistance data with vRNA rebound slopes showed that for NFV failures RT and PRO mutations were most frequent in the gradual rebounds (19/27) and ongoing replication groups (16/18), but not in the rapid rebounds (2/9). For 908 the few RT mutations observed were also either in the gradual rebounds (3/11) or in the ongoing replication group (1/9), not in the rapid rebounds (0/12).

Table 1

Table 1

Back to Top | Article Outline

Profile of PI resistance mutations selected (week 12 onwards)

Selection of PRO or cleavage site mutations by 908/r q.d. was not observed in virus from any of the first failure samples analysed (n = 32, Table 2), or from 12 patients who continued to receive 908/r q.d. despite evidence of ongoing replication, sampled at the last time-point on therapy (median, 8 weeks on continued failing regimen; range, 4–40 weeks). Similarly there was no evidence of reduced susceptibility to APV, or cross-resistance to any other PIs (Table 2). Only patient 1 who had baseline resistance and archived mutations, had reduced susceptibility to APV and saquinavir and resistance to indinavir, lopinavir (LPV), NFV and ritonavir (RTV) (Table 2).

NFV-associated PRO mutations D30N and/or L90M were selected in 39% (21/54) of NFV-treated virological failures. Seventeen (31%) had D30N and three (6%) L90M and one (2%) combined D30N/L90M. In addition, seven patients developed the primary resistance mutation M46I/L, two in the absence of D30N or L90M.

Back to Top | Article Outline

Selection of NRTI resistance mutations

ABC/3TC RT mutations were detectable in virus from four out of 32 patients in the 908/r q.d. arm (Table 1). Only mutations at RT position 184 (V or I) were selected, and a mixture D67d/n was found in virus from patient 2 (Table 2). All shifts in ABC-susceptibility were less than fourfold in magnitude. In the NFV b.i.d. arm, significantly more patients (69% versus 13%; P < 0.001) developed the M184I, V, or X (where X = m/i/v) RT mutations and three patients developed ABC mutations (K65R, n = 2; L74V, n = 1; Table 1).

Back to Top | Article Outline

Discussion

Analysis of the virological failure samples from patients in SOLO have revealed significantly lower incidence of the emergence of resistance to both the PI and NRTI components of the regimen in the 908/r q.d. arm compared with the NFV b.i.d. arm.

A regimen containing 908 might be expected to select PRO mutations similar to those observed with the active moiety APV [7]. However, in the virological failure population of SOLO, there was no evidence of selection by the 908/r q.d. regimen of any PRO mutations, which was confirmed by further analysis of virus from 11 patients up to 64 weeks of therapy. In addition, vRNA of nine patients re-suppressed while on study therapy, which is consistent with the lack of genotypic changes and absence of reduced susceptibility to APV (Table 2). No PI cross-resistance was observed except in patient 1, where archival resistance mutations contributed to phenotypic resistance to the six PIs tested.

The absence of the selection of PRO mutations by 908/r in SOLO, is reminiscent of observations made from Study M98-863 [13,14], in which antiretroviral-naive patients received d4T+3TC with either LPV/r b.i.d. or NFV b.i.d.. Isolates from 37 patients who received LPV/r for 48 weeks were analysed, and none developed resistance to LPV. Furthermore, of 76 NFV-treated patients analysed, 33% (25/76) demonstrated genotypic resistance (D30N or L90M) to NFV, compared with 39% (21/54) in SOLO.

Several factors may influence the emergence of resistance, including drug exposure, where absence of the development of resistance may be attributed either to very low or very high drug levels [15,16]. Low drug exposure, as may result from poor adherence, could provide insufficient antiviral pressure for resistance selection and permit replication of unaltered virus. Higher drug exposure, as observed with the 908/r q.d. regimen [2], may require the acquisition of multiple mutations, thereby delaying resistance development by provision of a high genetic barrier [13,14]. Evaluation of the viral load profiles in the NFV b.i.d. and 908/r q.d. arms revealed differences associated with the slopes of virological failure, and acquisition of mutations. This suggested that rapid rebounds which possibly result from stopping therapy are more frequently associated with few or no mutations, whereas gradual rebound or ongoing replication, possibly due to prolonged suboptimal drug exposure, are associated with acquisition of mutations. The high drug exposure of the 908/r regimen would be consistent with the greater genetic barrier producing a delay in the emergence of resistance to both PIs and NRTI. Questionnaire adherence data showed that the 908/r q.d. regimen had higher overall adherence than the NFV b.i.d. regimen, but that the 908/r q.d. virological failures were more frequently associated with poor adherence than the NFV b.i.d. virological failures, suggesting a lower barrier to resistance of the NFV arm [17].

In conclusion, the absence of emergent protease resistance to 908 or cross-resistance to other PI and reduced NRTI resistance during treatment with a 908/r q.d. regimen supports the use of this boosted PI early in the treatment continuum.

Back to Top | Article Outline

Acknowledgements

The authors thank the patients and investigators who participated in these studies, and ViroLogic Inc. for their contribution to the genotypic and phenotypic analyses. We wish to thank E. D. Blair for his technical writing assistance.

Back to Top | Article Outline

References

1. Nadler JP, Rodriguez-French A, Millard J, Wannamaker P. The NEAT Study: GW433908 Efficacy and Safety in ART-naïve subjects, Final 48-week analysis.Tenth Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [abstract 177].
2. Schurmann D. Efficacy and safety of GW433908/ritonavir once daily in therapy-naive subjects, 48 week results: the SOLO study. Sixth International Congress on Drug Therapy in HIV Infection. Glasgow, November 2002 (PL 14.4).
3. Falcoz, C, Jenkins JM, Bye C, Hardman TC, Kenney KC, Studenberg S, et al. Pharmacokinetics of GW433908, a prodrug of APV, in healthy male volunteers.J Clin Pharm 2002, 42:887–898.
4. Wood R, Trepo C, Livrozet JM, Avaslek K, Evon J, Kaur P, et al. Amprenavir (APV) 600 mg/ritonavir (RTV) 100 mg BID or APV 1200 mg/RTV 200 mg QD given in combination with abacavir (ABC) and lamivudine (3TC) maintains efficacy in ART-naive HIV-1 infected adults over 12 weeks (APV200I). Eighth Conference on Retroviruses and Opportunistic Infectious. Chicago, February 2001 (abstract 332).
5. Partaledis JA, Yamaguchi K, Tisdale M, Blair EE, Falcione C, Maschera B, et al. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease.J Virol 1995, 69:5228–5235.
6. Tisdale M, Myers RE, Maschera B, Parry NR, Oliver NM, Blair ED. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors.Antimicrobial Agents Chemother 1995, 39:1704–1710.
7. Maguire, M., Shortino D, Klein A, Harris W, Manohitharajah V, Tisdale M, et al. Emergence of resistance to protease inhibitor Amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to co-administered reverse transcriptase inhibitors.Antimicrobial Agents Chemother 2002, 46:731–738.
8. Maguire MF, Guinea R, Griffin P, MacManus S, Elston RC, Wolfram J, Richards N, et al. Changes in Human Immunodeficiency Virus type 1 Gag at positions L449 or P453 are linked to I50V protease mutantsin vivoand cause reduction of sensitivity to amprenavir and improved viral fitnessin vitro. J Virol 2002, 76:7398–7406.
9. International AIDS Society-USA 2002. Drug resistance in HIV-1 update. Topics HIV Med 2002 10:11–15.
10. Albrecht D, Zollner B, Feucht H, Lorenzen T, Laufs R, Stoehr A, et al. Reappearance of HIV multidrug resistance in plasma and circulating lymphocytes after reintroduction of antiretroviral therapy. J Clin Virol 2002, 24:93–98.
11. Yerly S, Rakik A, De Loes SK, Hirschel B, Deschamps D, Brun-Vezinet F, et al. Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants. J Virol 1998, 72:3520–3523.
12. Garcia–Lerma, JG, Nidtha S, Blumoff K, Heneine W. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV 1 from drug-naïve persons. Proc Nat Acad Sci USA 2001, 98: 13907–13912.
13. Bernstein B, Kempf D, King M, Mosely J, Cernohous P, Gu K, et al. Absence of resistance to Lopinavir/r (formerly known as ABT-378/r0 observed through 48 weeks of therapy in antiretroviral-naive subjects (M98-863 study). Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 453].
14. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, et al. Lopinavir-ritonavir verses nelfinavir for the initial treatment of HIV Infection. N Engl J Med 346:2039–2046.
15. Masquelier B, Breilh D, Neau D, Lawson-Ayayi S, Lavignolle V, Ragnaud J-M, et al. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob Agents Chemother 2002 46:2926–2932.
16. Masquelier B, Peytavin G, Leport C, Droz C, Duran S, Verdon R. Besnier J-M, et al. Mechanisms of early virologic failure in antiretroviral-naïve patients starting protease inhibitor- containing regimens: the APROVIR study. J Inf Dis 2002 186: 1503–1507.
17. Quattek K, Kotsopoulos N, Garris C, Elston R. The relationship between adherence and resistance in ART-naive subjects treated with 908/RTV QD or Nelfinavir (NFV) BID. Ninth European AIDS Conference. Warsaw, October 2003 [abstract 10.1/18].
18. Vaillancourt M., Irlbeck D, Smith T, Coombs R, Swanstrom R. The HIV 1 protease inhibitor saquinavir can select for multiple mutations that confer increasing resistance. AIDS Res Hum Retroviruses 1999, 15:355–363.
    Keywords:

    lack of resistance; phenotype; PI-boosting; GW433908; first-line therapy

    © 2004 Lippincott Williams & Wilkins, Inc.